BiotechTube
IcanoMAB

IcanoMAB

Munich, Germany· Est.
icanomab.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.5M

Overview

IcanoMAB is a German biotech developing a portfolio of canonical signaling monoclonal antibodies derived from a proprietary rabbit-based discovery platform. The company has secured three IND-enabling stage assets: a HER2newC apoptosis inducer for breast cancer, a CD40 agonist for immuno-oncology, and an IL-1R7 antagonist for acute inflammatory diseases like Covid-19 ARDS/CRS. Founded in 2013 by experienced pharma alumni, the private company is pre-revenue and plans to use funding to advance candidates through IND-enabling studies and seek strategic partnerships.

OncologyImmunologyInflammationInfectious Disease

Technology Platform

Proprietary rabbit monoclonal antibody discovery platform generating canonical signaling antibodies (agonistic or inhibitory) without extensive in vitro maturation, aiming for high precision and potency.

Funding History

1
Total raised:$5.5M
Seed$5.5M

Opportunities

Large, growing markets in oncology and immunology with clear unmet needs, particularly for safer CD40 agonists and novel anti-cytokine therapies validated by the Covid-19 pandemic.
The company's asset-centric partnership strategy could provide significant non-dilutive funding and de-risked development paths with established players.

Risk Factors

High pre-clinical development risk; intense competition in all target areas; dependence on a single technology source (MAB Discovery) and funding entity; the Covid-19 therapeutic landscape is rapidly evolving, potentially reducing urgency for its lead inflammatory candidate.

Competitive Landscape

Highly competitive. HER2 space is crowded with next-generation ADCs and bispecifics. Multiple CD40 agonists are in clinical trials, though limited by toxicity. Several companies are targeting the IL-18/IL-1 pathway for inflammation. IcanoMAB's differentiation hinges on its platform's ability to generate antibodies with superior canonical signaling and safety profiles.

More companies in Biologics / Biosimilars →More companies in Germany →